As a result of the firm's financial results, Castle Bio raised its full-year 2025 revenue guidance to between $327 and $335 million from a range of $310 to $320 million.

Last week, readers were most interested in a story about Biodesix's journey as a publicly traded company and what lies ahead for it.

Of the 30 companies in the index, 21 firms saw their share prices rise month over month, while nine saw their stock prices decline.

The Dublin-based firm is developing an array of artificial intelligence-derived tools to improve the efficiency of its digital pathology outsourcing service.

The blood-based test detects phosphorylated tau 181, a biomarker that is correlated with the presence of amyloid pathology in ...

Medicare Part B data show that of the 20 CPT codes seeing the largest increase in payments from 2022 to 2024, all are for molecular- or sequencing-based tests.

As the shutdown drags out, there could be delays in regulatory processes and payments for medical services as well as the possibility that legislative priorities will go unaddressed.

Called the RESULTS Act, the bill would use a third-party database to set Medicare payment rates and would delay price cuts and data reporting scheduled for 2026.

NEW YORK — Tosoh Bioscience said on Thursday that it has received 510 (k) clearance from the US Food and Drug Administration for its automated HLC-723 GR01 glycohemoglobin A1c (HbA1c) analyzer.

The Netherlands-based company will develop a low-cost, rapid point-of-care test using its Visualization by Infrared PEptide Reaction (VIPER) technology.

The projects include the development of rapid diagnostic tests for tuberculosis, Strongyloides stercoralis, and malaria.

The firm's full and mini gastrointestinal panel tests can now be used with fecal swab samples to detect pathogen nucleic acids.